A Case of Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease

Riku Arai, Daisuke Fukamachi, Masaki Monden, Naotaka Akutsu, Nobuhiro Murata and Yasuo Okumura

Abstract:
Ophthalmic carteolol is often used to treat glaucoma. Elderly patients with atrial fibrillation (AF) and chronic kidney disease (CKD) are common among the super-elderly in Japan. Because these patients are exposed to polypharmacy, they are at a high-risk of adverse drug interactions. We herein report an elderly patient with CKD who suffered bradycardia shock after the combined use of carteolol eye drops and verapamil for glaucoma and paroxysmal AF. This case highlights the fact that eye drops have a similar systemic effect to oral drugs, and especially in elderly patients with polypharmacy, drug interactions can unwittingly lead to serious events.

Key words: eye drops, carteolol, verapamil, chronic kidney disease, hyperkalemia

Introduction
Ophthalmic beta blockers, represented by timolol and carteolol, are often used to treat glaucoma in the elderly (1). As the elderly population is dramatically increasing in Japan, we often encounter elderly patients with atrial fibrillation (AF) and chronic kidney disease (CKD) (2). Because such patients tend to have multiple comorbidities, they often visit several medical institutions, and accordingly, they are prescribed multiple medications (i.e. polypharmacy). One clinical issue in those patients is that they may unwittingly experience drug interactions due to their polypharmacy, leading to a potential risk of adverse clinical events (3).

There have been two case reports of bradycardia with the combined use of timolol eye drops and verapamil, with their combined use first reported in the 20th century (4, 5). However, the interaction between carteolol eye drops and verapamil has not been reported. We herein report a case of bradycardia shock caused by the combined use of carteolol eye drops and verapamil in an elderly patient with a history of CKD and glaucoma, who suffered from paroxysmal AF (PAF).

Case Report
An 84-year-old woman presented with a 3-day history of shortness of breath and chest discomfort. She was determined to be frail as evaluated by a Canadian Study of Health and Aging Clinical Frailty Scale of 6 on admission. She had a history of glaucoma, hypertension, and CKD (estimated glomerular filtration rate 32.6 mL/min/1.73 m²) from over 10 years earlier and was being treated separately at ophthalmology and internal medicine outpatient clinics. She had blindness in her right eye due to glaucoma, and her left eye had been treated with ophthalmic carteolol and travoprost for the last few years. She had been taking azilsartan and doxazosin in addition to diet therapy for hypertension and CKD. As a result, she had been taking five kinds of internal medications, two kinds of external medications, and four kinds of eye drops a day, resulting in polypharmacy.

Five days before admission, she had been diagnosed with...
symptomatic PAF, so verapamil (40 mg twice a day [b.i.d.]) had been newly initiated by her internal medicine physician.

According to the information from the previous doctor, her heart rate had been about 60-80 beats/minute (bpm) before the start of verapamil. At admission, her heart rate was 29 bpm, and her blood pressure could not be obtained, although her radial artery pulse was palpable. Her respiratory rate and body temperature were 15/min and 36.0 °C, respectively.

Her laboratory data on admission are shown in Table, revealing high serum potassium, high liver enzyme, and high lactate levels. A 12-lead electrocardiogram (ECG) during the initial examination showed a heart rate of 24 bpm and narrow QRS rhythm followed by retrograde P-waves with a Wenckebach phenomenon without significant ST-segment changes (Fig. 1). Transthoracic echocardiography revealed a normal left ventricular function without any asynergy, D-shape, echo-free space, or valvular disease with a normal size of the left atrial diameter (32.0 mm). Chest X-ray revealed pulmonary edema and enlargement of the cardiothoracic ratio.

Her clinical course is shown in Fig. 2. Because she had bradycardia shock, represented by high serum lactate and liver enzyme levels, with hyperkalemia, a temporary pacing catheter was placed through the right internal jugular vein, and right ventricular pacing was performed at 90 bpm while administering an intravenous injection of calcium gluconate hydrate and glucose-insulin therapy for hyperkalemia. Anti-cholinergics could not be used due to glaucoma. With this treatment, the shock immediately resolved, and the symptoms disappeared. The carteolol eye drops, verapamil, and azilsartan were discontinued, and the patient was treated with a pacing rhythm until the next day (Fig. 3). The morning after she was hospitalized, her heart rhythm returned to

---

**Table. Laboratory Data at the Time of Admission.**

| WBC | 5,900 /mm3 | Na | 139 mEq/L |
|-----|------------|----|-----------|
| Hb  | 11.4 g/dL  | K  | 6.5 mEq/L |
| Plt | 14.2×10^4 /μL | Cl | 110 mEq/L |
| BUN | 35.6 mg/dL | Ca | 8.5 mg/dL |
| Cre | 1.21 mg/dL | T-Chol | 160 mg/dL |
| eGFR | 32.6 | HDL-Chol | 67 mg/dL |
| CCR | 21.25 | LDL-Chol | 66 mg/dL |
| CRP | 0.11 mg/dL | TG | 64 mg/dL |
| TP  | 5.2 g/dL   | U/A | 6.3 mg/dL |
| Alb | 3.0 g/dL   | CK | 66 U/L   |
| T-Bil | 1.20 mg/dL | CK-MB | 4 U/L |
| AST | 234 U/L    | Troponin I | 0.01 ng/mL |
| ALT | 119 U/L    | NT-proBNP | 3,722 pg/mL |
| LDH | 421 U/L    | TSH | 7.79 μlU/mL |
| ALP | 248 mEq/L  | Free T3 | 2.36 pg/mL |
| BS  | 157 mg/dL  | Free T4 | 1.20 ng/mL |
| HbA1c | 5.3 % | Lactate | 2.9 mmol/L |

Alb: albumin, ALT: alanine aminotransferase, AST: aspartate aminotransferase, BS: blood sugar, BUN: blood urea nitrogen, Ca: serum calcium, CCR: creatinine clearance, CK: creatine kinase, Cl: serum chloride, Cre: serum creatinine, CRP: C-reactive protein, eGFR: estimated glomerular filtration rate, Free T3: free triiodothyronine, Free T4: free thyroxine, Hb: hemoglobin, HbA1c: hemoglobin A1c, HDL-Chol: high density lipoprotein cholesterol, K: serum potassium, LDH: lactate dehydrogenase, LDL-Chol: low density lipoprotein cholesterol, Na: serum sodium, NT-proBNP: N-terminal pro-Brain Natriuretic Peptide, Plt: platelets, T-Bil: total bilirubin, T-Chol: total cholesterol, TG: triglyceride, TP: total protein, TSH: thyroid-stimulating hormone, UA: serum uric acid, WBC: white blood cells.

---

**Figure 1.** A 12-lead electrocardiogram during the initial examination. A heart rate of 24 bpm and a narrow QRS rhythm followed by retrograde P-waves with a Wenckebach phenomenon without significant ST-segment changes were noted.
Figure 2. Clinical course of this case. ALT: alanine aminotransferase, AST: aspartate aminotransferase, Calcic: calcium gluconate hydrate, GI: glucose-insulin therapy, HR: heart rate, PAF: paroxysmal atrial fibrillation, PMI: pacemaker intubation

Figure 3. A 12-lead electrocardiogram after initiating temporary pacing. A heart rate of 93 bpm, wide QRS rhythm with a left bundle branch block and upper axis pattern, and right ventricular apex origin were noted.

a normal sinus rhythm with a heart rate of 63 bpm (Fig. 4). The carteolol eye drops were discontinued after consultation with the ophthalmologist, and a different non-beta blocker for glaucoma (dorzolamide hydrochloride) was prescribed to protect her non-blind left eye. The bradycardia no longer appeared after normalization of the potassium level and discontinuing verapamil and the carteolol eye drops.

However, she had symptomatic PAF with a rapid ventricular response on the first hospital day. When the PAF stopped, she temporarily had a backup pacing with VVI 50 bpm due to sick sinus syndrome. Based on her clinical course, it was judged that the use of antiarrhythmic drugs alone for PAF carried a risk of bradycardia shock, so it was decided to administer antiarrhythmic drugs after pacemaker intubation.
implantation. However, pulmonary vein isolation was not selected due to her age and activity of daily living. Pacemaker implantation was performed on the 14th hospital day. Finally, her arrhythmia, blood pressure, and glaucoma were controlled with the pacemaker implantation and adjustment of her medications, as shown in Fig. 2, and she was discharged in good health on the 20th hospital day.

**Discussion**

Ophthalmic carteolol, as well as timolol, is used as an eye drop beta blocker for glaucoma. Carteolol has been considered to have a lower risk of cardiovascular events than timolol because carteolol generally has a weaker effect on slowing the heart rate than timolol, depending on the characterization of the intrinsic sympathomimetic activity (ISA) (6, 7). Although warning clues of cardiovascular events, such as bradycardia, heart block, and hypotension, have been reported due to the use of timolol eye drops (8), there have been no reports of severe cardiovascular events with the use of carteolol eye drops. Because timolol eye drops are absorbed via the nasal mucosa through the nasolacrimal duct, their bioavailability is approximately 50% of that after oral administration, and they have a systemic effect similar to oral administration; however, they are topically administered (9). Furthermore, because both carteolol and timolol are metabolized by cytochrome P450 2D6 (CYP 2D6), their effect can be enhanced in elderly people with a weakened CYP2D6 when combined with a drug with a CYP 2D6 inhibitory effect and/or verapamil (10).

Verapamil is a commonly used class IV antiarrhythmic medication that blocks calcium-dependent slow channels, depresses the cardiac contractility, slows the myocardial conduction, and relaxes vascular smooth muscle. It serves to decrease sino-atrial (SA) node discharges and slow atrioven-

![Figure 4. A 12-lead electrocardiogram the day after the hospitalization. A heart rate of 63 bpm with normal sinus rhythm and T-wave flattening in leads III and aVF were observed.](image_url)
Author’s disclosure of potential Conflicts of Interest (COI).

Yasuo Okumura: Research funding, Boston Scientific Japan.

Acknowledgement

We thank all of the doctors and medical staff who were involved in the treatment of this patient. In particular, Ph. So Iwabuchi and Ph. Takahiro Sekine provided important information about the carteolol eye drops. We also thank Mr. John Martin for his help with the English editing.

References

1. Quigley HA. Glaucoma. Lancet (London, England) 377: 1367-1377, 2011.
2. Lamprea-Montealegre JA, Zelnick LR, Shlipak MG, et al. Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. J Am Heart Assoc 8: e012200, 2019.
3. Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int 12: 761-762, 2012.
4. Sinclair NI, Benzie JL. Timolol eye drops and verapamil—a dangerous combination. Med J Aust 1: 548, 1983.
5. Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. Br Med J (Clin Res Ed) 294: 155-156, 1987.
6. Floreani M, Froldi G, Cavalli M, et al. Characterization of intrinsic sympathomimetic activity of carteolol in rat cardiovascular preparations. J Pharmacol Sci 95: 115-123, 2004.
7. Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol 123: 465-477, 1997.
8. Koch-Weser J, Frishman WH. beta-Adrenoceptor antagonists: new drugs and new indications. The New England journal of medicine 305: 500-506, 1981.
9. Alvan G, Calissendorff B, Seideman P, Widmark K, Widmark G. Absorption of ocular timolol. Clin Pharmacokinet 5: 95-100, 1980.
10. Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf 15: 1549-1561, 2016.
11. Hutchison SJ, Lorimer AR, Lakhdar A, McAlpine SG. Beta blockers and verapamil: a cautionary tale. Br Med J (Clin Res Ed) 289: 659-660, 1984.
12. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41: 67-76, 2009.
13. Kojima T, Akishita M, Nakamura T, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 12: 425-430, 2012.
14. Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 174: 347-354, 2014.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© The Japanese Society of Internal Medicine

Intern Med Advance Publication